Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL516868 | 1.00 | PIK3CD (0.38) | PIK3CDNR1H2NR1H3RECQLPOLB | |
| SCHEMBL517242 | 0.82 | RECQL (0.32) | RECQLPOLBHPGDPKMMEN1 | |
| SCHEMBL517241 | 0.82 | RECQL (0.32) | RECQLPOLBHPGDPKMMEN1 | |
| SCHEMBL19666476 | 0.77 | POLB (0.51) | RECQLPOLBHPGDPKMMEN1 | |
| SCHEMBL516710 | 0.77 | PIK3CD (0.45) | PIK3CDNR1H2NR1H3POLBHPGD | |
| SCHEMBL516709 | 0.77 | PIK3CD (0.45) | PIK3CDNR1H2NR1H3POLBHPGD | |
| SCHEMBL19465808 | 0.77 | PIK3CD (0.45) | PIK3CDNR1H2NR1H3POLBHPGD | |
| SCHEMBL19666475 | 0.77 | POLB (0.51) | RECQLPOLBHPGDPKMMEN1 | |
| SCHEMBL516711 | 0.77 | PIK3CD (0.45) | PIK3CDNR1H2NR1H3POLBHPGD | |
| SCHEMBL19064665 | 0.77 | PIK3CD (0.47) | PIK3CDRECQLPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | PIK3CD 1474/4885NR1H2 638/4885NR1H3 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.